INFLUENCE OF SOMATIC MUTATIONS OF KRAS, NRAS, BRAF AND MICROSATELLITE INSTABILITY STATUS ON SURVIVAL OF COLORECTAL CANCER PATIENTS WITH PERITONAL CARCINO

INFLUENCE OF SOMATIC MUTATIONS OF KRAS, NRAS, BRAF AND MICROSATELLITE INSTABILITY STATUS ON SURVIVAL OF COLORECTAL CANCER PATIENTS WITH PERITONAL CARCINO

Purpose: to evaluate the effect of somatic mutations of the KRAS, NRAS, BRAF genes and the status of microsatellite instability on the overall and disease-free survival of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.Material and Methods. From 2012 to 2018...

Full description

Bibliographic Details
Main Authors:	V. P. Shubin, Yu. A. Shelygin, S. I. Achkasov, O. I. Sushkov, A. A. Ponomarenko, A. I. Arzamastseva, A. S. Tsukanov
Format:	Article
Language:	Russian
Published:	Russian Academy of Sciences, Tomsk National Research Medical Center 2020-10-01
Series:	Сибирский онкологический журнал
Subjects:	колоректальный рак, перитонеальный карциноматоз, гены kras, nras, braf, микросателлитная нестабильность, выживаемость
Online Access:	https://www.siboncoj.ru/jour/article/view/1579

Similar Items

МИКРОСАТЕЛЛИТНАЯ НЕСТАБИЛЬНОСТЬ КОЛОРЕКТАЛЬНОГО РАКА В ДЕТСКОМ ВОЗРАСТЕ (КЛИНИЧЕСКОЕ НАБЛЮДЕНИЕ)
Published: (2017-04-01)

Clinical and morphological portrait of tumors with microsatellite instability
by: A. A. Musaelyan, et al.
Published: (2021-07-01)

The role of KRAS and NRAS mutation detection in determining the therapy strategy for colorectal cancer
by: A. N. Toropovskiy, et al.
Published: (2022-11-01)

PRESSURIZED INTRAPERITONEAL AEROSOL CHEMOTHERAPY COMBINED WITH SYSTEM CHEMOTHERAPY – A NEW APPROACH TO TREATMENT OF GASTRIC CANCER PATIENTS WITH PERITONAL CARCINOMATOSIS
by: V. M. Khomyakov, et al.
Published: (2020-09-01)

MICROSATELLITE INSTABILITY AS A MOLECULAR GENETIC MARKER OF DEFECTIVE MISMATCH REPAIR SYSTEM IN ESOPHAGEAL CANCER
by: О. I. Kit, et al.
Published: (2016-12-01)

Prognostic significance of PD-L1 expression and evaluation of microsatellite instability status in patients with retroperitoneal leiomyosarcomas
by: V. Е. Bugaev, et al.
Published: (2019-11-01)

МИКРОСАТЕЛЛИТНАЯ НЕСТАБИЛЬНОСТЬ КАК МОЛЕКУЛЯРНО-ГЕНЕТИЧЕСКИЙ МАРКЕР ПРИ РАКЕ ПИЩЕВОДА.
Published: (2016-01-01)

MICROSATELLITE-UNSTABLE COLORECTAL CANCER IN ELDERLY PATIENTS: CLINICAL FEATURES AND THE ROLE OF IMMUNODEFICIENCY
by: D. V. Pashkov, et al.
Published: (2020-03-01)

The Role of Genetic Mutations in the Prevention of Malignant Tumours in a Healthy Population (A Review)
by: O. N. Lipatov, et al.
Published: (2020-12-01)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
by: Sergiu Pasca, et al.
Published: (2019-10-01)

Efficient sequence of therapy for advanced and metastatic endometrial cancer
by: A. A. Rumyantsev
Published: (2022-09-01)

Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma
by: K. V. Menshikov, et al.
Published: (2023-01-01)

Genetic and morphological factors of nephritic survival rate
by: M I Churnosov, et al.
Published: (2009-12-01)

PERITONEAL CARCINOMATOSIS. REVIEW OF WORLD EXPERIENCE
by: S. V. Solomenny, et al.
Published: (2017-02-01)

Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer
by: İvo Gökmen, et al.
Published: (2023-09-01)

Clinical, anamnestic, molecular and genetic criteria for Lynch syndrome
by: A. V. Semyanikhina, et al.
Published: (2019-12-01)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
by: Aleksandra Bożyk, et al.
Published: (2021-03-01)

Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR
by: Yuki Nagakubo, et al.
Published: (2019-11-01)

COMBINATION OF LENVATINIB AND PEMBROLISUMAB IN THE TREATMENT OF ADVANCED ENDOMETRIAL CANCER: A CASE REPORT
by: O. N. Churuksaeva, et al.
Published: (2021-03-01)

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
by: Qiwei Yang, et al.
Published: (2018-10-01)

The combination of mutations in BRAF and NRAS genes within a one tumor in patients with cutaneous melanoma
by: M. B. Aksenenko, et al.
Published: (2019-10-01)

KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician
by: Afrăsânie Vlad-Adrian, et al.
Published: (2019-09-01)

NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children
by: Tianyou Yang, et al.
Published: (2019-05-01)

Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma
by: Moltara Maja Ebert, et al.
Published: (2018-04-01)

IMMUNOHISTOCHEMICAL STUDY OF MSH2, MSH6, PMS2, MLH1 IN EVALUATION OF DIFFERENTIATION GRADE OF COLON ADENOCARCINOMA
by: G. A. Raskin, et al.
Published: (2016-02-01)

FREQUENCY OF NRAS AND KRAS GENES IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS
by: Sidra Barlas, et al.
Published: (2020-04-01)

Relationship between KRAS and NRAS factors with clinicopathologic findings in patients with metastatic colon cancer
by: Hamid Saeidi Saedi, et al.
Published: (2023-03-01)

Transarterial chemoembolization in the treatment of primary and recurrent pelvic tumors with peritoneal involvement: what results can be expected?
by: E. A. Zvezdkina, et al.
Published: (2022-09-01)

Relationship between the transcriptional activity of СT-genes and survival in colorectal cancer patients
by: D. S. Kutilin, et al.
Published: (2022-03-01)

Determination of the Prevalence of Microsatellite Instability, <i>BRAF</i> and <i>KRAS</i>/<i>NRAS</i> Mutation Status in Patients with Colorectal Cancer in Slovakia
by: Tomas Rendek, et al.
Published: (2024-03-01)

Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience
by: Edita Baltruškevičienė, et al.
Published: (2016-04-01)

KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal Cancer
by: Zeng J, et al.
Published: (2023-09-01)

Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma
by: Fanny Barel, et al.
Published: (2017-09-01)

Ascitic ovarian cancer is an adequate preclinical model of carcinomatosis to study intraperitoneal chemoperfusion treatment
by: G. S. Kireeva, et al.
Published: (2019-02-01)

Mutational profile of KRAS, NRAS, BRAF, PIK3CA, and AKT1 genes in colorectal cancer patients in a tertiary care hospital, Dhaka
by: Sharmin Chowdhury, et al.
Published: (2022-10-01)

<i>KRAS, NRAS, BRAF, HER2</i> and MSI Status in a Large Consecutive Series of Colorectal Carcinomas
by: Aleksandr S. Martianov, et al.
Published: (2023-03-01)

ABERRANT METHYLATION OF THE PROMOTER OF APC, CDH13 AND MGMT GENES IN COLORECTAL CANCER PATIENTS
by: O. I. Kit, et al.
Published: (2016-07-01)

KRAS and NRAS genes mutations as biomarkers in the therapy of colorectal cancer and the basic methods of their detection
by: Olga I. Brovkina, et al.
Published: (2021-03-01)

Analysis of KRAS, NRAS, and BRAF Mutations, Microsatellite Instability, and Relevant Prognosis Effects in Patients With Early Colorectal Cancer: A Cohort Study in East Asia
by: Yang Li, et al.
Published: (2022-06-01)

Identification of <i>NRAS</i> Downstream Genes with CRISPR Activation Screening
by: Akiya Tatsumi, et al.
Published: (2022-10-01)